Anthracycline cardiomyopathy

0Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Anthracycline antibiotics are highly effective in the treatment of cancer, but their cardiotoxicity limits use of these antibiotics. A cardiotoxic action of anthracyclines provokes development of dilated cardiomyopathy with or without symptoms of cardiac insufficiency (CI). Anthracyclines have a long-term cardiotoxic action, therefore, with time, the rate of cardiomyopathy development increases. Follow-up echocardiography is an optimal method for assessment of cardiac function. Such parameters as left ventricular ejection fraction and the degree of the anteroposterior shortening are most essential. Cardiac failure symptoms are managed in the same way as in other pathology.

Cite

CITATION STYLE

APA

Anokhin, V. N., Chushkin, M. I., & Kolganov, A. V. (2011). Anthracycline cardiomyopathy. Terapevticheskii Arkhiv. https://doi.org/10.1161/circheartfailure.118.005194

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free